Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
7.40    0.00 (0.00%)
Bid:
7.30
Ask:
7.50
Spread: 0.20 (2.74%)
Market Cap: £3.24m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

CCI Exclusive Distributor Agreement with Korea ISG

8 Jun 2017 13:15

RNS Number : 5678H
Feedback PLC
08 June 2017
 

8 June 2017

Feedback plc

 

("Feedback" or the "Company")

 

CCI Exclusive Distributor Agreement with Korea ISG

 

Feedback plc (AIM: FDBK), the medical imaging software company, is pleased to announce that its subsidiary Cambridge Computed Imaging Ltd ("CCI") has signed an Exclusive Distributor arrangement with Korea Computer Motion ISG ("Korea ISG") based in Seoul, South Korea, for sales and distribution of its TexRAD® texture analysis research software ("TexRAD").

TexRAD will be used by customers for research purposes, performing advanced analysis of routinely acquired medical diagnostic images (e.g. CT, MRI) in South Korea.

As outlined in CCI's recent investor presentations, this is a significant step for CCI as part of its plans to expand sales of TexRAD software to meet the fast-growing demand in Asian markets, identifying and engaging with distributors who are experts in the local market, and who can leverage the TexRAD brand awareness to help build a regional sales pipeline.

Dr Balaji Ganeshan, CEO of TexRAD and Director of New Business at Feedback said:

 "We are pleased to sign this significant Distributorship agreement with Korea ISG to support the interest and acceptance of TexRAD in the rapidly growing and important South Korean medical imaging research market. We are confident that by working with an experienced team led by the CEO Jacob Woo, who has a great understanding of the market and customer base, we stand to increase the TexRAD revenue potential and market reach and meet our customer needs."

Mr Jacob Woo, CEO of Korea ISG commented, "

"We are pleased to have started to work with CCI this year to promote the highly acclaimed TexRAD texture analysis software in South Korea which has attracted a lot of interest amongst the top university hospitals who are also our potential customers. Following a recent installation for research at the prestigious Korea University Hospital, I anticipate a very successful business relationship, rapidly increasing TexRAD software sales and working closely with Dr. Balaji Ganeshan and CCI. Our team has a first class reputation amongst researchers in the region, and offers unrivalled in-depth market-access and know-how in South Korea."

 

About CCI

CCI Ltd is owned by Feedback, based in Bourn, Cambridge, UK. CCI focusses on the development and supply of advanced software including TexRAD, for texture analysis of medical images and storage and interpretation of imaging data.

About Korea Motion ISG

Korea ISG has installed and supported MRI/CT 3D processing imaging software to about 120 prominent Korean hospitals for 23 years, and is the largest medical imaging software distribution (sales and service/support) company in South Korea. They are experienced distributors of medical software from other world leading suppliers, with a wide customer base.

About TexRAD

TexRAD is a highly advanced, patented image texture analysis software tool that analyses routinely acquired diagnostic medical images (e.g. CT, MRI) to reveal features that are not always evident to the human eye. The platform also comprises a novel data-mining tool to assist the research customer to undertake statistical analysis to identify interesting parameters demonstrating association with patient outcome and clinical parameters. A number of research studies published in numerous peer-reviewed journals and conference presentations show that TexRAD texture metrics may have the potential to predict prognosis, disease severity and treatment prediction/evaluation in a number of cancer applications.

 

 

For further information, please contact:

Feedback plcAlastair Riddell

Tel: 01954 718072

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAOKFDKBBKDCAK
Date   Source Headline
22nd Apr 20262:10 pmRNSGrant of Options and PDMR dealing
20th Apr 20267:00 amRNSNHS Progress and Business Update
17th Feb 202610:43 amRNSCorrection: Half-year Report
17th Feb 20267:00 amRNSHalf-year Report
2nd Feb 20267:00 amRNSNotice of Results & Retail Investor Presentation
5th Jan 20264:13 pmRNSHolding(s) in Company
23rd Dec 20253:44 pmRNSHolding(s) in Company
23rd Dec 20253:44 pmRNSHolding(s) in Company
23rd Dec 20253:33 pmRNSDirector/PDMR Shareholding
23rd Dec 20253:33 pmRNSDirector/PDMR Shareholding
18th Dec 20257:00 amRNSTrading Update
20th Oct 20257:00 amRNSDirectorate Change
13th Oct 20254:04 pmRNSResult of AGM
18th Sep 20251:07 pmRNSNotice of AGM
17th Sep 20257:00 amRNSFinal Results
8th Sep 20257:00 amRNSNotice of Results & Retail Investor Presentation
10th Jul 20257:00 amRNSGrant of Options and PDMR dealing
12th Jun 20257:00 amRNS-RNeighbourhood Health Service Simulation
7th May 202510:44 amRNSHolding(s) in Company
6th May 20251:01 pmRNSHolding(s) in Company
28th Apr 20257:00 amRNSTrading Update
25th Feb 20257:00 amRNSHalf-year Report
11th Feb 20257:00 amRNSNotice of Results & Investor Presentation
14th Jan 20257:00 amRNSSurrender and grant of options and PDMR dealings
18th Dec 20243:07 pmRNSHolding(s) in Company
18th Dec 20247:00 amRNSHalf Year Trading Update
9th Dec 202410:56 amRNSHolding(s) in Company
9th Dec 202410:48 amRNSHolding(s) in Company
4th Dec 20247:00 amRNSHolding(s) in Company
3rd Dec 202412:33 pmRNSHolding(s) in Company
3rd Dec 202412:18 pmRNSHolding(s) in Company
2nd Dec 202411:53 amRNSHolding(s) in Company
2nd Dec 202411:46 amRNSHolding(s) in Company
2nd Dec 20247:00 amRNSDirector/PDMR Shareholding
29th Nov 20243:36 pmRNSHolding(s) in Company
29th Nov 20243:33 pmRNSHolding(s) in Company
28th Nov 20242:35 pmRNSResult of AGM & Commercial Update
6th Nov 20247:00 amRNSResult of WRAP Retail Offer
4th Nov 20243:46 pmRNSSuccessful Fundraising upscaled to c. £5.57m
4th Nov 20247:02 amRNSWRAP Retail Offer for up to £1 million
4th Nov 20247:01 amRNSProposed Fundraise & Share Capital Reorganisation
4th Nov 20247:00 amRNSFinal Results
16th Oct 20247:00 amRNSElective Recovery Fund funding mechanism
19th Sep 20247:00 amRNSCollaboration Agreement
2nd Sep 20247:00 amRNSFurther funding to extend NHS Trust pathways
10th Jul 20247:00 amRNSVertex In Healthcare Collaboration
1st Jul 20247:00 amRNSCDC Contract Awarded by Queen Victoria Hospital
28th Jun 20247:00 amRNSChange of Name of Nominated Adviser and Broker
22nd May 20247:00 amRNSTrading Update
25th Mar 20247:00 amRNSNew tuberculosis partnership in India

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.